Please login to the form below

Not currently logged in
Email:
Password:

Zelluna Immunotherapy appoints chief technology officer

Arjan Roozen will consolidate the biotech’s manufacturing strategy

Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.

Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.

Roozen’s career history has also seen him serve in numerous positions for Pharmacell, which was recently acquired by Lonza.

Miguel Forte, chief executive officer of Zelluna, said: “Zelluna appointed Arjan specifically for his wide-ranging knowledge in key areas of cell therapy product manufacturing.

“His experience, acquired on both side’s of the Atlantic will provide invaluable for Zelluna in its immediate focus of delivering clinical proof of concept of its TCRs in adoptive cell therapy for solid cancers.

“He will play a big part in the execution of Zelluna’s manufacturing strategy for clinical trials and commercialisation.”

20th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics